Portal de Periódicos da CAPES

Once-daily oral deferasirox for the treatment of transfusional iron overload

2008; Taylor & Francis; Volume: 1; Issue: 2 Linguagem: Inglês

10.1586/17512433.1.2.231

1751-2441

Renzo Galanello, Raffaella Origa,

Erythropoietin and Anemia Treatment

The increasing use of blood transfusions, combined with extended patient survival, has led to an increase in the number of patients at risk of developing transfusional iron overload. Clinical data have shown that the once-daily oral iron chelator deferasirox is effective in adults and children with various transfusion-dependent anemias, including β-thalassemia and the myelodysplastic syndromes. Deferasirox has a defined, clinically manageable safety profile. The most common treatment-related adverse events are mild gastrointestinal disorders, skin rash and mild, nonprogressive serum creatinine increases. The deferasirox clinical trial program is continuing in Phase II/III extension phases and Phase IV trials. Long-term data continue to support the efficacy and safety of deferasirox. Convenient, effective and tolerable chelation therapy with deferasirox is a significant development in the treatment of transfusional iron overload.